Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
Valneva has raised $43.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Valneva's investors include Bpifrance, Cormorant Asset Management, Vivo Capital, Pfizer, TCG Crossover.
Valneva is headquartered in Saint-herblain, France.
Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
Valneva is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Valneva — Funding & Investors." VCBacked, April 30, 2026, https://www.vcbacked.co/company/valneva. Accessed November 12, 2026.
VCBacked. (2026). Valneva — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/valneva
{{cite web |title=Valneva — Funding & Investors |url=https://www.vcbacked.co/company/valneva |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Valneva? Request a listing update